Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K. Kijima T, et al. Among authors: ishioka j. BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28. BJU Int. 2012. PMID: 22369348
Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.
Numao N, Yoshida S, Komai Y, Ishii C, Kagawa M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. Numao N, et al. Among authors: ishioka j. J Urol. 2013 Aug;190(2):502-8. doi: 10.1016/j.juro.2013.02.3197. Epub 2013 Mar 7. J Urol. 2013. PMID: 23473904
Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor.
Yoshida S, Takahara T, Arita Y, Ishii C, Uchida Y, Nakagawa K, Toda K, Sakamoto T, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Yoshimura R, Fujii Y. Yoshida S, et al. Among authors: ishioka j. Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):376-381. doi: 10.1016/j.ijrobp.2019.06.011. Epub 2019 Jun 12. Int J Radiat Oncol Biol Phys. 2019. PMID: 31201896
Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy.
Kijima T, Tanaka H, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Kijima T, et al. Among authors: ishioka j. Clin Genitourin Cancer. 2020 Aug;18(4):268-273.e2. doi: 10.1016/j.clgc.2019.11.005. Epub 2019 Dec 4. Clin Genitourin Cancer. 2020. PMID: 31883941
87 results